Mark C. Gebhardt - Concepedia

Author

Mark C. Gebhardt

Also Known As

D Ciaroni, Gebhardt, Mark, Gebhardt, Mark C., M C Gebhardt, M Gebhardt, M. C. GEBHARDT, M. C. Gebhardt, M. Gebhardt, M.C. Gebhardt, MARK C. GEBHARDT

328

Publications

27.2K

Citations

H-Index

146

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Boston Children's Hospital Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute

About

Mark C. Gebhardt is an author at Massachusetts General Hospital specializing in medicine, orthopaedics, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	84	9.8K
2	Health Sciences	12	13	1.5K
3	Engineering	2	2	73
4	Natural Sciences	2	2	218
5	Law	1	1	25

Mark C. Gebhardt

163

Publications

24.1K

Citations

H-Index

Page 1

	Year	Citations
A System for the Functional Evaluation of Reconstructive Procedures After Surgical Treatment of Tumors of the Musculoskeletal System Mark C. Gebhardt, Martin Malawar, Douglas Pritchard Clinical Orthopaedics and Related Research	1993	2.2K
Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone Holcombe E. Grier, Mark Krailo, Nancy J. Tarbell, New England Journal of Medicine	2003	1.3K
p53 functions as a cell cycle control protein in osteosarcomas. Lisa Diller, J Kassel, C. Nelson, Molecular and Cellular Biology Wild-type P53Oncogenic AgentP53 GeneMedicinePathology	1990	766
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group Paul A. Meyers, Cindy L. Schwartz, Mark Krailo, Journal of Clinical Oncology	2008	734
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate Paul A. Meyers, Cindy L. Schwartz, Mark Krailo, Journal of Clinical Oncology	2005	711
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan, European Journal of Cancer	2019	700
Long-Term Results of Allograft Replacement in the Management of Bone Tumors Henry J. Mankin, Mark C. Gebhardt, L. Candace Jennings, Clinical Orthopaedics and Related Research	1996	667
Percutaneous Radiofrequency Coagulation of Osteoid Osteoma Compared with Operative Treatment* Daniel I. Rosenthal, Francis J. Hornicek, Michael W. Wolfe, Journal of Bone and Joint Surgery Surgical OncologyOsteopathyInterventional RadiologySurgerySpinal Oncology	1998	587
Osteoid Osteoma: Percutaneous Treatment with Radiofrequency Energy Daniel I. Rosenthal, Francis J. Hornicek, Martin Torriani, Radiology	2003	519
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial Neyssa Marina, Sigbjørn Smeland, Stefan Bielack, The Lancet Oncology	2016	511

Page 1